ROTTERDAM – Rotterdam Study
Maryam Kavousi - Erasmus Medical Center, Rotterdam, the Netherlands
M. Arfan Ikram - Erasmus University Medical Center, Rotterdam, the Netherlands
The Rotterdam Study (ROTTERDAM) is a general population study based in Rotterdam, Netherlands. Subjects 55 years old or older living in the suburb of Ommoord in Rotterdam were enrolled in the study. The principal aim of the study was to investigate determinants of frequent diseases in an elderly population. The study was approved by the Medical Ethics Committee of Erasmus University, and written informed consent was obtained from all participants.
Link to study webpage – http://www.erasmus-epidemiology.nl/research/ergo.htm
The Rotterdam Study has been supported by Akzo Nobel, Alzheimer’s Association, Astra Pharmaceutial N.V., AstraZeneca, Bayer AG, Blindenpenning Foundation, Amsterdam, Brainfoundation of the Netherlands, Bristol-Myers Squibb, Center of Medical Systems Biology (CMSB), Dutch Diabetes Research Foundation, Dutch Kidney Foundation, Dutch Arthritis Association, Elise Mathilde Foundation, Maarn, Erasmus Medical Center, Erasmus University Rotterdam, European Commission, Foundation for Helping the Blind, The Hague, Foundation for the Ophthalmic Diseased, Rotterdam, Foundation G.Ph. Verhagen, General Electric Healthcare, Glaxo Smith Kline, International Foundation Alzheimer’s Research, Inspectorate for Health Care, Janivo Foundation, K.F. Hein Foundation, Merck Sharp & Dohme, Haarlem, Municipality of City of Rotterdam, National Epilepsy Fund, National Health Fundraising Foundation, National Institute on Aging, NIH, Bethesda, MD, USA, National Society for the Blind and Visually Impaired (LSBS), Netherlands Foundation for the Blind and Visually Handicapped, Netherlands Heart Foundation, Netherlands Institute for Health Sciences (Nihes), Netherlands Ophthalmic Research Institute, Netherlands Organisation for Health Research and Development (ZonMw), Netherlands Organisation for Scientific Research (NWO), Netherlands Society for the Prevention of Blindness, Netherlands Thrombosis Foundation, Novo Nordisk, Numico Research B.V., OOG Foundation, The Hague, N.V. Organon, Oxagen, Optimix Foundation, Amsterdam, Physicotherapeutic Institute, Prinses Beatrix Foundation, Procter & Gamble, Research Institute for Diseases in the Elderly (RIDE), Rotterdam Foundation for Ophthalmic Research, Rotterdam Foundation for the Interests of the Blind, St Laurens Institute, Rotterdam, Topcon Europe B.V., Trustfund Erasmus University Rotterdam, Unilever, and Van Leeuwen Van Lignac Foundation, Rotterdam.
Common Carotid Intima-Media Thickness and Lower Extremity Arterial Atherosclerosis: The Rotterdam Study. Arterioscler Thromb. 1994 Dec;14(12):1885-91
Common Carotid Intima-Media Thickness and Risk of Stroke and Myocardial Infarction: The Rotterdam Study. Circulation. 1997 Sep 2;96(5):1432-7
Predictive Value of Noninvasive Measures of Atherosclerosis for Incident Myocardial Infarction: The Rotterdam Study. Circulation. 2004 Mar 9;109(9):1089-94
Coronary Calcification Improves Cardiovascular Risk Prediction in the Elderly. Circulation. 2005 Jul 26;112(4):572-7
Association of atherosclerosis with presence and progression of osteoarthritis: the Rotterdam Study. Ann Rheum Dis. 2013 May;72(5):646-51
The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol. 2013 Nov;28(11):889-926